prikaz prve stranice dokumenta Efficacy and safety of colistin in the treatment of infections caused by multidrug-resistant Pseudomonas aeruginosa in patients with hematologic malignancy: a matched pair analysis
  Download
PDF 219.47 KB
Scientific paper - Original scientific paper
Efficacy and safety of colistin in the treatment of infections caused by multidrug-resistant Pseudomonas aeruginosa in patients with hematologic malignancy: a matched pair analysis
Internal Medicine, 50 (2011), 9; 1009-1013. https://doi.org/10.2169/internalmedicine.50.4270
Duraković, Nadira; Radojčić, Vedran; Boban, Ana; Mrsić, Mirando; Sertić, Dubravka; Serventi-Seiwerth, Ranka; Nemet, Damir; Labar, Boris

Institutional repository: Dr Med - University of Zagreb School of Medicine Digital Repository

Cite this document

Duraković, N., Radojčić, V., Boban, A., Mrsić, M., Sertić, D., Serventi Seiwerth, R. ... Labar, B. (2011). Efficacy and safety of colistin in the treatment of infections caused by multidrug-resistant Pseudomonas aeruginosa in patients with hematologic malignancy: a matched pair analysis. Internal Medicine, 50. (9), 1009-1013. doi: 10.2169/internalmedicine.50.4270

Duraković, Nadira, et al. "Efficacy and safety of colistin in the treatment of infections caused by multidrug-resistant Pseudomonas aeruginosa in patients with hematologic malignancy: a matched pair analysis." Internal Medicine, vol. 50, no. 9, 2011, pp. 1009-1013. https://doi.org/10.2169/internalmedicine.50.4270

Duraković, Nadira, Vedran Radojčić, Ana Boban, Mirando Mrsić, Dubravka Sertić, Ranka Serventi Seiwerth, Damir Nemet and Boris Labar. "Efficacy and safety of colistin in the treatment of infections caused by multidrug-resistant Pseudomonas aeruginosa in patients with hematologic malignancy: a matched pair analysis." Internal Medicine 50, no. 9 (2011): 1009-1013. https://doi.org/10.2169/internalmedicine.50.4270

Duraković, N., et al. (2011) 'Efficacy and safety of colistin in the treatment of infections caused by multidrug-resistant Pseudomonas aeruginosa in patients with hematologic malignancy: a matched pair analysis', Internal Medicine, 50(9), pp. 1009-1013. doi: 10.2169/internalmedicine.50.4270

Duraković N, Radojčić V, Boban A, Mrsić M, Sertić D, Serventi Seiwerth R, and sur.. Efficacy and safety of colistin in the treatment of infections caused by multidrug-resistant Pseudomonas aeruginosa in patients with hematologic malignancy: a matched pair analysis. Internal Medicine [Internet]. 2011 [cited 2024 November 30];50(9):1009-1013. doi: 10.2169/internalmedicine.50.4270

N. Duraković, et al., "Efficacy and safety of colistin in the treatment of infections caused by multidrug-resistant Pseudomonas aeruginosa in patients with hematologic malignancy: a matched pair analysis", Internal Medicine, vol. 50, no. 9, pp. 1009-1013, 2011. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:105:311976. [Accessed: 30 November 2024]

Metadata
Title (english)Efficacy and safety of colistin in the treatment of infections caused by multidrug-resistant Pseudomonas aeruginosa in patients with hematologic malignancy: a matched pair analysis
AuthorNadira Duraković
AuthorVedran Radojčić
AuthorAna Boban
AuthorMirando Mrsić
AuthorDubravka Sertić
AuthorRanka Serventi-Seiwerth
AuthorDamir Nemet
AuthorBoris Labar
Author's institutionUniversity of Zagreb
School of Medicine
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Abstract (english)
OBJECTIVE: A rise in infections with multidrug-resistant Pseudomonas aeruginosa (MDR-PA) is a significant contributor to increased morbidity and mortality of patients with hematologic malignancies. The aim of this study was to determine the efficacy and safety of colistin (colistimethate sodium) in the treatment of serious infections caused by MDR-PA in these patients. ----- PATIENTS AND METHODS: A matched pair analysis of renal function, toxicities, and outcome of 26 patients receiving colistin and control subjects was done. All patients had clinical signs of sepsis; P. aeruginosa was isolated from blood in 69% of patients in colistin group and 84% in control group. Patients treated with colistin received 3 million units every 8 hours for a median duration of 13 days. Additionally, patients received at least two additional antimicrobial or antifungal drugs. ----- RESULTS: Resolution of infection was achieved in twenty patients (76.9%) receiving colistin and in 17 (65.4%) control subjects. Mortality rate was 11% in both groups. There was no statistically significant difference in the level of serum creatinine, creatinine clearance, or potassium levels before and after treatment between groups. Only one patient receiving colistin developed de novo renal failure and one displayed transient neurologic toxicity. ----- CONCLUSION: Our results suggest that in patients with hematologic malignancies, colistin is effective in treating severe infections caused by MDR-PA while maintaining an acceptable toxicity profile. Prospective randomized studies comparing efficacy and safety of colistin with those of other antipseudomonal drugs are needed.
Keywords (english)
Languageenglish
Publication typeScientific paper - Original scientific paper
Publication statusPublished
Peer reviewPeer review
Publication versionPublished version
Journal titleInternal Medicine
Numberingvol. 50, no. 9, pp. 1009-1013
p-ISSN0918-2918
DOIhttps://doi.org/10.2169/internalmedicine.50.4270
URN:NBNurn:nbn:hr:105:311976
Publication2011
Document URLhttps://doi.org/10.2169/internalmedicine.50.4270
Type of resourceText
Access conditionsOpen access
Terms of useLicence In copyright icon
Created on2024-03-27 19:03:52